DDInter1397 DDInter1484
Paroxetine is a selective serotonin reuptake inhibitor (SSRI) drug commonly known as Paxil. It has a variety of uses, including the treatment of anxiety disorders, major depression, posttraumatic stress disorder, and symptoms of menopause, among others. It was approved by the FDA in the early 1990s and marketed by SmithKline Beecham.[L7712,L7715] A unique feature of this drug is that it is highly potent and selective in its inhibition of serotonin reuptake and has little effect on other neurotransmitters. Because of its potent inhibition of serotonin reuptake, paroxetine is more likely to cause withdrawal effects upon cessation. Paroxetine is well tolerated in most patients with a similar adverse effect profile to other members of its drug class. The controlled release formulation was designed to decrease the likelihood of nausea that is sometimes associated with paroxetine.[L7700,L7742]
Plicamycin is an antineoplastic antibiotic produced by Streptomyces plicatus. It has been used in the treatment of testicular cancer, Paget's disease of bone, and, rarely, the management of hypercalcemia. The manufacturer discontinued plicamycin in 2000.
Paroxetine {u} (Compound) upregulates {v} (Gene) IKBKB
IKBKB {u} (Gene) is upregulated by {v} (Compound) Gatifloxacin
Gatifloxacin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Plicamycin
Paroxetine {u} (Compound) downregulates {v} (Gene) RPS4Y1
RPS4Y1 {u} (Gene) is downregulated by {v} (Compound) Gatifloxacin
Gatifloxacin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Plicamycin
Paroxetine {u} (Compound) upregulates {v} (Gene) IKBKB
IKBKB {u} (Gene) is upregulated by {v} (Compound) Chloramphenicol
Chloramphenicol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Plicamycin
Paroxetine {u} (Compound) downregulates {v} (Gene) RPS4Y1
RPS4Y1 {u} (Gene) is downregulated by {v} (Compound) Chloramphenicol
Chloramphenicol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Plicamycin
Paroxetine {u} (Compound) upregulates {v} (Gene) IKBKB
IKBKB {u} (Gene) is upregulated by {v} (Compound) Ponatinib
Ponatinib {u} may lead to a major life threatening interaction when taken with {v} Plicamycin
Paroxetine {u} (Compound) downregulates {v} (Gene) PGAM1
PGAM1 {u} (Gene) is downregulated by {v} (Compound) Ponatinib
Ponatinib {u} may lead to a major life threatening interaction when taken with {v} Plicamycin
Paroxetine {u} (Compound) upregulates {v} (Gene) IKBKB
IKBKB {u} (Gene) is upregulated by {v} (Compound) Dasatinib
Dasatinib {u} may lead to a major life threatening interaction when taken with {v} Plicamycin
Paroxetine {u} (Compound) downregulates {v} (Gene) PGAM1
PGAM1 {u} (Gene) is downregulated by {v} (Compound) Omacetaxine mepesuccinate
Omacetaxine mepesuccinate {u} may lead to a major life threatening interaction when taken with {v} Plicamycin
Paroxetine {u} (Compound) downregulates {v} (Gene) RBM34
RBM34 {u} (Gene) is upregulated by {v} (Compound) Omacetaxine mepesuccinate
Omacetaxine mepesuccinate {u} may lead to a major life threatening interaction when taken with {v} Plicamycin
Paroxetine {u} (Compound) upregulates {v} (Gene) BNIP3L
BNIP3L {u} (Gene) is downregulated by {v} (Compound) Gatifloxacin
Gatifloxacin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Plicamycin
Paroxetine (Compound) upregulates IKBKB (Gene) and IKBKB (Gene) is upregulated by Gatifloxacin (Compound) and Gatifloxacin may cause a minor interaction that can limit clinical effects when taken with Plicamycin
Paroxetine (Compound) downregulates RPS4Y1 (Gene) and RPS4Y1 (Gene) is downregulated by Gatifloxacin (Compound) and Gatifloxacin may cause a minor interaction that can limit clinical effects when taken with Plicamycin
Paroxetine (Compound) upregulates IKBKB (Gene) and IKBKB (Gene) is upregulated by Chloramphenicol (Compound) and Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Plicamycin
Paroxetine (Compound) downregulates RPS4Y1 (Gene) and RPS4Y1 (Gene) is downregulated by Chloramphenicol (Compound) and Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Plicamycin
Paroxetine (Compound) upregulates IKBKB (Gene) and IKBKB (Gene) is upregulated by Ponatinib (Compound) and Ponatinib may lead to a major life threatening interaction when taken with Plicamycin
Paroxetine (Compound) downregulates PGAM1 (Gene) and PGAM1 (Gene) is downregulated by Ponatinib (Compound) and Ponatinib may lead to a major life threatening interaction when taken with Plicamycin
Paroxetine (Compound) upregulates IKBKB (Gene) and IKBKB (Gene) is upregulated by Dasatinib (Compound) and Dasatinib may lead to a major life threatening interaction when taken with Plicamycin
Paroxetine (Compound) downregulates PGAM1 (Gene) and PGAM1 (Gene) is downregulated by Omacetaxine mepesuccinate (Compound) and Omacetaxine mepesuccinate may lead to a major life threatening interaction when taken with Plicamycin
Paroxetine (Compound) downregulates RBM34 (Gene) and RBM34 (Gene) is upregulated by Omacetaxine mepesuccinate (Compound) and Omacetaxine mepesuccinate may lead to a major life threatening interaction when taken with Plicamycin
Paroxetine (Compound) upregulates BNIP3L (Gene) and BNIP3L (Gene) is downregulated by Gatifloxacin (Compound) and Gatifloxacin may cause a minor interaction that can limit clinical effects when taken with Plicamycin